Home / Expertise / Intellectual Property

Intellectual Property

Netherlands

In today’s knowledge economy, a large part of the value of your business is based on intangible assets and goodwill. Your intellectual property plays a key role in obtaining a competitive advantage. A cohesive IP strategy, including both commercialisation and enforcement, will ensure you get maximum value from your portfolio. With 150 specialist lawyers in over 30 countries, we understand your business needs and have worked with some of the best-known brands, from banks to tech and media companies, pharmaceuticals and FMCG companies. This industry-specific approach can help you realise your commercial goals.

The right brands will win the hearts and minds of your customers. The right patents will prevent others exploiting your ideas or provide a substantial barrier to market access. Copyright, know-how and designs also play a vital role. Legal discussions might arise concerning trade names, advertisements, slavish imitation and unauthorized publications.

We focus on key sectors relevant to you such as lifesciences, automotive, machinery, manufacturing, consumer products, financial services and TMC. This means you get in-depth industry knowledge as well as legal expertise for the protection of your IP. If you are involved in a dispute - concerning infringement of a copyright for example - we can guide you through the litigation process.

Significant clients: UEFA, Pioneer, Syngenta, Diageo, Ogilvy.

Read more Read less

"The firm draws praise for the co-ordination of its international network."

Chambers Global, 2020

"CMS has a huge network and I can always trust to receive seamless and high-quality legal advice, regardless of borders."

Chambers Global, 2020

"The CMS team provides assistance on privacy, anti-competition, and data ownership issues."

The Legal 500, 2019

The team "provides excellent service and has branches and partners in different jurisdictions."

Chambers Europe, 2019

"Cross-border capabilities really add to the customer experience."

Chambers Global, 2019

"Prompt, friendly and personalised service, depth of knowledge and quick grasp of the issues."

Chambers Europe, 2018

"Outstanding knowledge of, and experience in, a wide range of IP matters."

The Legal 500, 2018
Sub­scribe to In­tel­lec­tu­al Prop­erty top­ics
June 2019
CMS In­tel­lec­tu­al Prop­erty Glob­al Bro­chure

Feed

Show only
20/01/2020
The in­tel­lec­tu­al prop­erty di­lem­mas caused by AI-gen­er­ated...
03 Feb 20
SkyKick: Good news for brand own­ers - the CJEU's rul­ing main­tains...
Sum­mary The eagerly awaited judg­ment in the SkyKick case (C-371/18) was pub­lished on Wed­nes­day. The case relates to ques­tions re­ferred to the CJEU by the UK High Court in trade mark in­fringe­ment pro­ceed­ings...
24/12/2019
DNB pub­lishes re­gis­tra­tion form for crypto ser­vice...
31 Jan 20
UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
21/11/2019
CMS ad­vised Arkance on the ac­quis­i­tion of Dutch-Bel­gian...
31 Jan 20
A Short Guide: Pri­or­ity En­ti­tle­ment at the EPO
Art­icle 87 EPC Pri­or­ity right (1) Any per­son who has duly filed, in or for (a) any State party to the Par­is Con­ven­tion for the Pro­tec­tion of In­dus­tri­al Prop­erty or (b) any Mem­ber of the World Trade Or­gan­iz­a­tion,...
08/11/2019
CMS ad­vises Arkance Sys­tems on the ac­quis­i­tion of CAD...
15 Jan 20
Can newly dis­covered can­nabis com­pounds be pro­tec­ted by pat­ents?
A break­through dis­cov­ery has re­cently hit the news: tet­rahy­drocan­nabi­phorol (THCP) and can­na­bid­i­phorol (CB­DP), two new can­nabin­oid com­pounds, have been dis­covered in Can­nabis sativa and char­ac­ter­ised...
27 Aug 19
Con­sumer Products News­let­ter
In­tel­lec­tu­al Prop­erty and Un­fair Com­pet­i­tion law
20 Dec 19
‘Dar­unavir’ CJEU re­fer­ral with­drawn - Art­icle 3(a) of the SPC Reg­u­la­tion
At the end of Septem­ber, we re­por­ted here on the pub­lic­a­tion of AG Hogan’s Opin­ion on the joint re­fer­rals from the Ger­man Bundes­pat­ent­gericht (case C-650/17) for Mer­ck’s sitaglipt­in product and from...
August 2019
How block­chain will re­volu­tion­ise the gam­ing in­dustry
17 Dec 19
The rise of pat­ent wars in Europe’s gene ther­apy space
The gene ther­apy in­dustry is in an ex­cit­ing phase of growth, un­der­go­ing sig­ni­fic­ant M&A activ­ity, product sales and new mar­ket­ing au­thor­isa­tions that are be­ing is­sued with in­creas­ing reg­u­lar­ity glob­ally....